Short Interest in Genfit S.A. (NASDAQ:GNFT) Declines By 6.3%

Genfit S.A. (NASDAQ:GNFT) was the recipient of a significant drop in short interest in December. As of December 15th, there was short interest totalling 59,800 shares, a drop of 6.3% from the November 30th total of 63,800 shares. Approximately 0.1% of the shares of the stock are sold short. Based on an average daily volume of 12,300 shares, the days-to-cover ratio is currently 4.9 days.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and issued a $13.00 price target on shares of Genfit in a research note on Friday, October 11th.

Genfit Stock Up 0.5 %

GNFT opened at $3.71 on Thursday. The company has a quick ratio of 3.74, a current ratio of 3.74 and a debt-to-equity ratio of 0.61. The company has a fifty day moving average of $4.46 and a 200 day moving average of $4.51. Genfit has a fifty-two week low of $3.31 and a fifty-two week high of $6.42.

Genfit Company Profile

Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.